{"final_output": "The first clinical trial is a study of 89Zr-girentuximab for PET imaging of solid tumors likely to express high levels of CAIX. The patient has soft tissue sarcoma that started in the stomach and spread to the liver, which meets the eligibility criteria for this clinical trial. The contact information for this clinical trial is Kavita Vadali, Global Clinical Trials, Telix Pharma, phone: +61 3 9093 3808, email: global-clinicaltrials@telixpharma.com. The patient is a good fit for this clinical trial because they have soft tissue sarcoma, which is a solid tumor, and the clinical trial is studying the use of 89Zr-girentuximab for PET imaging of solid tumors likely to express high levels of CAIX."}